Mycophenolate versus Cyclophosphamide for Lupus Nephritis.

about

Mycophenolate or Cyclophosphamide in Lupus Nephritis: Which One to Use in Indian Patients?

P2860

Q55166851-5C3C5242-4DF2-4024-9B52-221023AAF3AE

P2860

Mycophenolate versus Cyclophosphamide for Lupus Nephritis.

Item

http://www.wikidata.org/entity/Q54260329

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Mycophenolate versus Cyclophosphamide for Lupus Nephritis.

@en

Mycophenolate versus Cyclophosphamide for Lupus Nephritis.

@nl

type

Item

label

Mycophenolate versus Cyclophosphamide for Lupus Nephritis.

@en

Mycophenolate versus Cyclophosphamide for Lupus Nephritis.

@nl

prefLabel

Mycophenolate versus Cyclophosphamide for Lupus Nephritis.

@en

Mycophenolate versus Cyclophosphamide for Lupus Nephritis.

@nl

P1476

Mycophenolate versus Cyclophosphamide for Lupus Nephritis.

@en

P2093

K Ismal

http://www.w3.org/2001/XMLSchema#string

M Sahay

http://www.w3.org/2001/XMLSchema#string

P S Vali

http://www.w3.org/2001/XMLSchema#string

Y Saivani

http://www.w3.org/2001/XMLSchema#string

P2860

Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis.

The classification of glomerulonephritis in systemic lupus erythematosus revisited.

Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis

The outcome of proliferative lupus nephritis with pulse cyclophosphamide therapy

American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis

Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis.

Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials.

Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide.

Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.

Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.

P304

35-40

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4103/IJN.IJN_2_16

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29515299

http://www.w3.org/2001/XMLSchema#string

P932

5830807

http://www.w3.org/2001/XMLSchema#string

Mycophenolate versus Cyclophosphamide for Lupus Nephritis.

about

P2860

P2860

Mycophenolate versus Cyclophosphamide for Lupus Nephritis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932